CareDx, Inc. faces uncertainty due to proposed reimbursement changes impacting its core testing business. William Blair initiated coverage, highlighting the company’s transition to consistency. Analyst Andrew F. Brackmann views CareDx as undervalued, with a focus on the transplant ecosystem. CareDx reported lower-than-expected earnings and narrowed sales guidance for fiscal 2025.

The company appointed Nathan Smith as CFO, succeeding Abhishek Jain. Brackmann notes uncertainty from a proposed local coverage decision affecting testing services. Shares trade at a discount to peers, with a fair value closer to $20 per share. CareDx has faced challenges including reimbursement issues, patent disputes, and regulatory probes.

William Blair believes CareDx has potential for share price appreciation, revenue growth, and momentum. The stock may trade sideways until the policy impact is finalized, at which point shares could rise. CareDx’s position in the transplant market and undervaluation make it an interesting opportunity for investors.

Read more at Yahoo Finance: CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential